Molecules Associated With the Presence and Severity of Nonalcoholic Fatty Liver Disease
Molecules Associated With the Presence and Severity of Nonalcoholic Fatty Liver Disease
Non-invasive diagnosis and treatment of nonalcoholic fatty liver disease (NAFLD) remain unmet
 medical needs. Aim of this study is to investigate the blood levels of three hormonal systems
 related to obesity, insulin resistance and inflammation in patients with different stages of
 NAFLD, in order to identify potential diagnostic markers.

 Study aim: To compare the blood levels of: a) proglucagon-derived hormones (glucagon-like
 peptide [GLP]-1, GLP-2, glicentin, oxyntomodulin, glucagon, major proglucagon fragment
 [MPGF]), b) follistatins-activins (follistatin-like (FSTL)3, activin B), c) IGF axis
 (insulin-like growth factor (IGF)-1, total and intact IGF binding protein (IGFBP)-3 and
 IGFBP-4, in 18 individuals with early stage NAFLD vs. 14 controls
Inclusion Criteria:

 -  Individuals with liver ultrasound imaging

 -  Adults

 Exclusion Criteria:

 -  The presence of any secondary cause of fatty liver, such as viral, alcoholic,
 autoimmune and drug-induced hepatitis.